Cellectis (CLLS) Free Cash Flow (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.72% |
| Dec 31, 2025 | -3,038.72% |
| Sep 30, 2025 | 96.10% |
| Jun 30, 2025 | 40.32% |
| Mar 31, 2025 | -259.53% |
| Dec 31, 2024 | 7.70% |
| Sep 30, 2024 | -109.49% |
| Jun 30, 2024 | 330.41% |
| Mar 31, 2024 | -154.27% |
| Dec 31, 2023 | 353.65% |
| Sep 30, 2023 | 10.62% |
| Jun 30, 2023 | 33.22% |
| Sep 30, 2022 | -12.98% |
| Jun 30, 2022 | -244.51% |
| Sep 30, 2021 | -286.71% |
| Jun 30, 2021 | 39.51% |
| Mar 31, 2021 | 89.61% |
| Dec 31, 2020 | -450.97% |
| Sep 30, 2020 | -133.75% |
| Jun 30, 2020 | -187.99% |
| Mar 31, 2020 | 130.72% |
| Dec 31, 2019 | -77.54% |
| Sep 30, 2019 | 5.68% |
| Jun 30, 2019 | 11.51% |
| Mar 31, 2019 | 25.78% |
| Dec 31, 2018 | -101.29% |
| Sep 30, 2018 | -14.89% |
| Jun 30, 2018 | 38.00% |
| Mar 31, 2018 | -40.55% |
| Dec 31, 2017 | 7.67% |
| Sep 30, 2017 | 9.05% |
| Jun 30, 2017 | -4.13% |
| Mar 31, 2017 | 36.00% |
| Dec 31, 2016 | -4,387.12% |
| Sep 30, 2016 | 107.15% |
| Jun 30, 2016 | 43.91% |
| Mar 31, 2016 | -150.57% |
| Dec 31, 2015 | 674.94% |
| Sep 30, 2015 | 71.79% |
| Jun 30, 2015 | -1,110.96% |